Skip to content
Clinical Trials – home

WIP Warsaw IBD Point Profesor Kierkus

Verified siteinfo

Poland Ul. Plowiecka 103, 04-501 Warsaw, Poland

  • 59 trials recruiting
  • Colitis ulcerative · Crohn's disease · Metabolic dysfunction-associated steatohepatitis
  • Adults and children

About Specializations

WIP Warsaw IBD Point Profesor Kierkus in Warsaw, Poland specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Metabolic dysfunction-associated steatohepatitis, Eosinophilic oesophagitis, and other specialisations. This site conducts important research.

Main research areas of the site

Inflammatory Bowel Disease Research

The WIP Warsaw IBD Point focuses on ulcerative colitis and Crohn's disease, aiming to test new therapies that can induce and maintain clinical remission. Studies explore both biologic and small‑molecule agents to improve patient outcomes.

  • Induction of remission with novel anti‑integrin agents
  • Maintenance strategies using dual‑biologic combinations
  • Assessing endoscopic healing through advanced imaging
  • Evaluating steroid‑free treatment targets

The site enrolls adult and pediatric participants, providing a platform for long‑term safety monitoring and real‑world effectiveness data.

Liver Metabolism and Fibrosis Studies

Research at the centre includes non‑alcoholic steatohepatitis (NASH) and other metabolic liver disorders, with trials designed to reduce liver fibrosis and improve histologic outcomes.

  • Evaluating anti‑fibrotic agents in patients with compensated cirrhosis
  • Testing RNA‑based therapies for alpha‑1 antitrypsin deficiency‑associated liver disease
  • Assessing metabolic benefits of combined SGLT2 inhibitor regimens
  • Long‑term safety of novel steatosis‑targeting compounds

These studies aim to provide new treatment options for patients with progressive liver disease and metabolic dysfunction.

Cardiovascular and Heart Failure Trials

The institution conducts investigations into heart failure with preserved ejection fraction and related cardiovascular risks, comparing combination therapies to standard care.

  • Comparing dual SGLT2 inhibitor therapy versus monotherapy
  • Measuring impact on cardiovascular mortality and hospitalisation
  • Exploring renal outcomes in patients with impaired kidney function
  • Safety profiling of novel cardio‑metabolic agents

Findings are intended to guide clinicians in managing complex heart failure patients with metabolic comorbidities.

Dermatology and Immune‑Mediated Skin Conditions

Trials address atopic dermatitis and related skin disorders, focusing on targeted immunomodulators that aim to achieve clear skin with minimal side effects.

  • Phase studies of IL‑4/IL‑13 pathway inhibitors
  • Assessing quality‑of‑life improvements in moderate‑to‑severe disease
  • Long‑term safety of biologic agents in adolescent populations
  • Biomarker analysis for treatment response prediction

The research supports personalized therapeutic approaches for patients with chronic inflammatory skin disease.

Respiratory and Infectious Disease Investigations

The site evaluates therapies for influenza and other respiratory infections, including susceptibility studies of antiviral agents.

  • Monitoring resistance patterns to baloxavir marboxil
  • Assessing transmission dynamics within households
  • Safety evaluation of novel antiviral compounds
  • Immunogenicity profiling in vaccinated cohorts

Results aim to improve public‑health responses and treatment guidelines for seasonal influenza.

Rare Genetic and Hereditary Disorders

Research includes hereditary angioedema and homozygous familial hypercholesterolemia, testing innovative gene‑targeted and enzyme‑replacement strategies.

  • Gene‑silencing therapies for angioedema attacks
  • Evaluating LDL‑lowering monoclonal antibodies in HoFH
  • Safety monitoring of long‑term enzyme replacement
  • Exploring genotype‑phenotype correlations for personalized care

These efforts seek to provide effective options for patients with few existing treatments.

Pediatric Inflammatory Bowel Disease Focus

Dedicated studies on children and adolescents with IBD assess age‑appropriate dosing and safety of subcutaneous biologics and oral small molecules.

  • Pharmacokinetic profiling of vedolizumab in pediatric UC
  • Evaluating remission rates with oral etrasimod in adolescents
  • Long‑term safety of guselkumab in juvenile Crohn's disease
  • Combination therapy outcomes after failure of first‑line biologics

The goal is to expand therapeutic choices for younger patients while ensuring rigorous safety standards.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Ul. Plowiecka 10304-501 WarsawPoland
Recruiting now
59 trials
Conditions studied
29
Partner status
Verified site

More sites in WarsawPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

120 clinical trials

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:MH002
  • Sponsor:Microbial Resource Management Health

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid
  • Sponsor:Eli Lilly & Co.

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

Study of icotrokinra for adults with moderately to severely active Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.